

Ascendiant Capital Markets LLC serves as Financial Advisor on \$2,000,000 Registered Direct for Daxor Corporation

IRVINE, Calif., March 5, 2020 -- Ascendiant Capital Markets LLC ("Ascendiant") announced today the closing of a \$2,000,000 Registered Direct Offering for Daxor Corporation (NYSE American: DXR) of New York, New York.

Ascendiant served as Financial Advisor on the transaction.

Daxor intends to use the net proceeds for working capital and other general corporate purposes.

About Daxor Corporation

Daxor Corporation (NYSE American: DXR) is an innovative medical instrumentation and biotechnology company focused on blood volume measurement. Daxor developed and markets the BVA-100® (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. The BVA technology has the potential to improve hospital performance metrics in a broad range of surgical and medical conditions including heart failure and critical care by better informing treatment strategies, resulting in significantly better patient outcomes. For more information please visit www.daxor.com.

About Ascendiant Capital Markets LLC

Ascendiant Capital Markets, LLC, based in Irvine, California, is a full-service investment banking, equity research, market making, and securities trading firm focused on public and private companies, and institutional, accredited, and strategic investors.

Ascendiant has led or participated in over \$1 billion in financing transactions, and the members of Ascendiant's Investment Banking Team have completed over 300 M&A transactions.

Ascendiant Capital Markets is registered with the United States Securities and Exchange Commission (SEC) as a broker-dealer, and is a member of the FINRA and SIPC.

For more information, please visit www.ascendiant.com or contact Bradley J. Wilhite, Co-Founder & Managing Partner, at 949.259.4949 or bwilhite@ascendiant.com.

This announcement shall not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.